Publications by authors named "Thomas Bachelot"

100Publications

A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016".

Eur J Cancer 2020 Nov 3;140:165-166. Epub 2020 Oct 3.

Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.09.005DOI Listing
November 2020

Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer.

Curr Opin Oncol 2020 Nov;32(6):555-560

Centre Léon Bérard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000682DOI Listing
November 2020

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Clin Cancer Res 2020 Oct 21;26(20):5310-5319. Epub 2020 Jul 21.

Division of Medical Oncology, Department of Internal Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-1764DOI Listing
October 2020

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

N Engl J Med 2020 02 11;382(7):597-609. Epub 2019 Dec 11.

From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) - both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology-Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H., D.S.), and Stanford Comprehensive Cancer Institute, Palo Alto (M.P.) - both in California; Dana-Farber Cancer Institute, Boston (N.U.L., I.K., E.P.W.); University of Colorado Cancer Center, Aurora (V.B.); Duke Cancer Institute, Durham (C.A.), and University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (L.A.C.) - both in North Carolina; University Health Network, Princess Margaret Cancer Centre, Toronto (P.L.B.), and British Columbia Cancer, Vancouver (K.G.) - both in Canada; Hospital Universitario Vall D'Hebron, Barcelona (M.O.); Sygehus Lillebaelt-Vejle Sygehus, Vejle, Denmark (E.J.); Centre Léon Bérard, Lyon, France (T.B.); Rambam Health Care Campus, Haifa, Israel (S.S.S.); Universitaetsklinikum Hamburg-Eppendorf, Hamburg (V.M.), and German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Hospital Cuf Descobertas R. Mário Botas, Lisbon, Portugal (S.B.); Cliniques Universitaires Saint-Luc, Brussels (F.P.D.); Third Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); Istituto Europeo di Oncologia, IRCCS, University of Milan, Milan (G.C.); and Seattle Genetics, Bothell, WA (M.C.P.-W., L.W., W.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914609DOI Listing
February 2020

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.

Breast Cancer 2018 Jan 16;25(1):17-27. Epub 2017 Nov 16.

Medical Oncology Department, Centre Leon Berard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0818-4DOI Listing
January 2018

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Eur J Cancer 2017 04 24;75:245-258. Epub 2017 Feb 24.

Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy; Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.026DOI Listing
April 2017

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Breast Cancer Res Treat 2016 06 11;157(2):307-318. Epub 2016 May 11.

Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3828-6DOI Listing
June 2016

PI3K targeting in breast cancer: the end of the beginning?

Lancet Oncol 2016 06 4;17(6):696-697. Epub 2016 May 4.

Centre Léon Bérard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00148-0DOI Listing
June 2016

[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

Bull Cancer 2016 May 15;103(5):507-10. Epub 2016 Mar 15.

Centre Léon-Bérard, département d'oncologie médicale, 69008 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.02.005DOI Listing
May 2016

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Cancer Chemother Pharmacol 2016 Feb 16;77(2):385-92. Epub 2016 Jan 16.

Institut Claudius-Regaud, IUCT-O, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2953-yDOI Listing
February 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].

Bull Cancer 2015 Jun;102(6 Suppl 1):S47-52

Département de médecine, Centre Léon-Bérard, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(15)31217-0DOI Listing
June 2015

[Quinze questions importantes à se poser en oncologie en 2015].

Bull Cancer 2015 Jun;102(6 Suppl 1):S22-6

Centre Léon-Berard, & Cancer Research Center of Lyon 28, rue Laennec, 69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(15)31214-5DOI Listing
June 2015

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

Bull Cancer 2015 Apr 21;102(4):367-80. Epub 2015 Mar 21.

Centre Léon-Bérard, 69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.02.013DOI Listing
April 2015

Therogenetics: transferring GWAS technology to the clinic.

Mutagenesis 2015 Mar;30(2):213-5

Université de Lyon, F-69000 Lyon, France, Université Lyon 1, F-69100 Villeurbanne, France, INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France and Centre Léon Bérard, F-69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/mutage/geu060DOI Listing
March 2015

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.

Cancer Treat Rev 2015 Feb 30;41(2):94-104. Epub 2014 Dec 30.

Royal Melbourne Hospital, Grattan St., Parkville, Melbourne 3050, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372140021
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2014.12.011DOI Listing
February 2015

A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Mol Oncol 2014 Dec 10;8(8):1441-57. Epub 2014 Jun 10.

ISPB, Faculté de Pharmacie, Lyon, France; Université Lyon 1, Lyon, France; INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528595PMC
December 2014

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer.

Int J Cancer 2014 Sep 4;135(6):1307-18. Epub 2014 Mar 4.

Université de Lyon, France; Université Lyon 1, France; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, France; Equipe Labellisée "La Ligue", Lyon, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.28781
Publisher Site
http://dx.doi.org/10.1002/ijc.28781DOI Listing
September 2014

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.

Cancer Lett 2014 Feb 14;343(1):33-41. Epub 2013 Sep 14.

Université de Lyon, Centre Léon Bérard, Département d'Oncologie Médicale, 28 rue Laennec, 69008 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2013.09.011DOI Listing
February 2014

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Target Oncol 2014 Jun 14;9(2):111-22. Epub 2013 Jul 14.

Department of Clinical Research, Institut Curie, Paris, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-013-0287-4DOI Listing
June 2014

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

Clin Cancer Res 2013 Jul 8;19(13):3693-702. Epub 2013 May 8.

Department of Medical Oncology, INSERM Unit U981, Paris Sud University, Institut Gustave-Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0190DOI Listing
July 2013

Targeted treatments for breast cancer: a step forward.

Lancet Oncol 2013 May 18;14(6):438-9. Epub 2013 Apr 18.

Departement de Cancerologie Medicale, Centre de Recherche en, Cancerologie de Lyon, Centre Leon Berard, 69373 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70153-0DOI Listing
May 2013

mTOR inhibitors in advanced breast cancer: ready for prime time?

Cancer Treat Rev 2013 Nov 1;39(7):742-52. Epub 2013 Apr 1.

Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.02.005DOI Listing
November 2013

Reply to J.-H. Choi et al.

J Clin Oncol 2013 Feb;31(4):511

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7399DOI Listing
February 2013